These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2069877)

  • 1. A multicentre trial to compare a loading dose regimen of tamoxifen ('Nolvadex') with conventional dosing in the treatment of advanced breast cancer. The British Tamoxifen Study Group.
    Spooner D; Fairlamb D; Fermont D
    Clin Oncol (R Coll Radiol); 1991 May; 3(3):133-6. PubMed ID: 2069877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum and urine levels of tamoxifen and its metabolites in patients with advanced breast cancer after a loading dose and at steady-state levels.
    de Vos D; Slee PH; Briggs RJ; Stevenson D
    Cancer Chemother Pharmacol; 1998; 42(6):512-4. PubMed ID: 9788580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer.
    Margreiter R; Wiegele J
    Breast Cancer Res Treat; 1984; 4(1):45-8. PubMed ID: 6365211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tamoxifen (Nolvadex) therapy--radionale for loading dose followed by maintenance dose for patients with metastatic breast cancer.
    Wilkinson PM; Ribiero GG; Adam HK; Kemp JV; Patterson JS
    Cancer Chemother Pharmacol; 1982 Dec; 10(1):33-5. PubMed ID: 7160042
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd.
    Bratherton DG; Brown CH; Buchanan R; Hall V; Kingsley Pillers EM; Wheeler TK; Williams CJ
    Br J Cancer; 1984 Aug; 50(2):199-205. PubMed ID: 6380554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.
    Muss HB; Case LD; Atkins JN; Bearden JD; Cooper MR; Cruz JM; Jackson DV; O'Rourke MA; Pavy MD; Powell BL
    J Clin Oncol; 1994 Aug; 12(8):1630-8. PubMed ID: 8040675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules.
    Fabian C; Sternson L; Barnett M
    Cancer Treat Rep; 1980; 64(6-7):765-73. PubMed ID: 7427961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data.
    Fabian C; Sternson L; El-Serafi M; Cain L; Hearne E
    Cancer; 1981 Aug; 48(4):876-82. PubMed ID: 7272932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial.
    Westerberg H
    Cancer Treat Rep; 1980 Jan; 64(1):117-21. PubMed ID: 6991101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial.
    Singh L; Wilson AJ; Baum M; Whimster WF; Birch IH; Jackson IM; Lowrey C; Palmer MK
    Br J Cancer; 1988 Jun; 57(6):612-4. PubMed ID: 3044433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A comparison of two doses of tamoxifen in patients with advanced breast cancer: 20 mg/day versus 40 mg/day].
    Takatsuka Y; Yayoi E; Inaji H; Aikawa T
    Gan To Kagaku Ryoho; 1989 May; 16(5):2093-7. PubMed ID: 2658841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.
    Br J Cancer; 1988 Jun; 57(6):608-11. PubMed ID: 2900647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tamoxifen (Nolvadex): therapeutic effect in metastasizing breast cancer].
    Mouridsen HT; Palshof T; Patterson J; Battersby L
    Ugeskr Laeger; 1979 Jul; 141(31):2108-13. PubMed ID: 483408
    [No Abstract]   [Full Text] [Related]  

  • 15. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer.
    Buzdar AU; Hortobagyi GN; Frye D; Ho D; Booser DJ; Valero V; Holmes FA; Birmingham BK; Bui K; Yeh C
    J Clin Oncol; 1994 Jan; 12(1):50-4. PubMed ID: 8270984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
    Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
    J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
    Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
    Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer.
    Tormey DC; Lippman ME; Edwards BK; Cassidy JG
    Ann Intern Med; 1983 Feb; 98(2):139-44. PubMed ID: 6824247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical assessment of loading dose tamoxifen for advanced breast carcinoma.
    Ribeiro GG; Wilkinson PM
    Clin Oncol; 1984 Dec; 10(4):363-7. PubMed ID: 6509818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.